Last $16.23 USD
Change Today -0.23 / -1.40%
Volume 58.7K
DRNA On Other Exchanges
Symbol
Exchange
NASDAQ GS
As of 5:10 PM 12/24/14 All times are local (Market data is delayed by at least 15 minutes).

dicerna pharmaceuticals inc (DRNA) Snapshot

Open
$16.50
Previous Close
$16.46
Day High
$16.59
Day Low
$16.19
52 Week High
01/30/14 - $46.00
52 Week Low
11/6/14 - $8.00
Market Cap
288.5M
Average Volume 10 Days
468.6K
EPS TTM
$-201.92
Shares Outstanding
17.8M
EX-Date
--
P/E TM
--
Dividend
--
Dividend Yield
--
Current Stock Chart for DICERNA PHARMACEUTICALS INC (DRNA)

Related News

No related news articles were found.

dicerna pharmaceuticals inc (DRNA) Related Businessweek News

No Related Businessweek News Found

dicerna pharmaceuticals inc (DRNA) Details

Dicerna Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the discovery and development of treatments for liver diseases and cancers based on a proprietary RNA interference technology platform in the United States and internationally. The company’s development programs include DCR-PH1 for the treatment of primary hyperoxaluria 1 (PH1) through targeting the liver metabolic enzyme glycolate oxidase; and other rare inherited diseases involving disease target genes expressed in the liver, including hemophilia, porphyria, hypercholesterolemia, hemoglobinopathies, alpha-1-antitrypsin deficiency hepatocyte, inclusions, and others. It is also developing DCR-M1711 for the treatment of various cancers through targeting the MYC oncogene, a gene that causes or promotes cancer when abnormally expressed or activated, as well as a product candidate targeting the oncogene KRAS; and a second product candidate targeting an oncogene. The company has a research collaboration and license agreement with Kyowa Hakko Kirin Co., Ltd. for the research, development, and commercialization of drug delivery platforms and DsiRNA molecules for therapeutic targets, primarily in oncology; and a license agreement with City of Hope, an academic research and medical center, to manufacture, use, offer for sale, sell, and import products related to DsiRNA for the prevention and treatment of various diseases in humans. Dicerna Pharmaceuticals, Inc. was founded in 2006 and is headquartered in Watertown, Massachusetts.

22 Employees
Last Reported Date: 03/27/14
Founded in 2006

dicerna pharmaceuticals inc (DRNA) Top Compensated Officers

Co-Founder, Chief Executive Officer, Presiden...
Total Annual Compensation: $375.0K
Chief Financial Officer and Principal Account...
Total Annual Compensation: $65.4K
Chief Scientific Officer and Senior Vice Pres...
Total Annual Compensation: $315.0K
Chief Business Officer
Total Annual Compensation: $295.0K
Compensation as of Fiscal Year 2013.

dicerna pharmaceuticals inc (DRNA) Key Developments

Dicerna Pharmaceuticals, Inc. Reports Unaudited Consolidated Earnings Results for the Third Quarter and Nine Months Ended September 30, 2014

Dicerna Pharmaceuticals, Inc. reported unaudited consolidated earnings results for the third quarter and nine months ended September 30, 2014. For the quarter, the company reported that loss from operations was $11,214,000 compared to $3,732,000 a year ago. Net loss attributable to common stockholders was $11,193,000 or $0.63 per basic and diluted share compared to $4,540,000 or $161.55 per basic and diluted share a year ago. Non-GAAP basic and diluted loss per share was $0.54 compared to $142.51 a year ago. Non-GAAP net loss was $9,586,000 compared to $4,005,000 a year ago. For the nine months, the company reported that loss from operations was $30,484,000 compared to $10,941,000 a year ago. Net loss attributable to common stockholders was $33,553,000 or $2.17 per basic and diluted share compared to $14,178,000 or $505.45 per basic and diluted share a year ago. Non-GAAP basic and diluted loss per share was $1.59 compared to $422.99 a year ago. Non-GAAP net loss was $24,566,000 compared to $11,865,000 a year ago.

Dicerna Pharmaceuticals, Inc. to Report Q3, 2014 Results on Nov 06, 2014

Dicerna Pharmaceuticals, Inc. announced that they will report Q3, 2014 results at 9:00 AM, Eastern Standard Time on Nov 06, 2014

Dicerna Pharmaceuticals, Inc., Q3 2014 Earnings Call, Nov 06, 2014

Dicerna Pharmaceuticals, Inc., Q3 2014 Earnings Call, Nov 06, 2014

 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
DRNA:US $16.23 USD -0.23

DRNA Competitors

Market data is delayed at least 15 minutes.

Company Last Change
No competitor information is available for DRNA.
View Industry Companies
 

Industry Analysis

DRNA

Industry Average

Valuation DRNA Industry Range
Price/Earnings NM Not Meaningful
Price/Sales -- Not Meaningful
Price/Book 2.6x
Price/Cash Flow NM Not Meaningful
TEV/Sales -- Not Meaningful
 | 

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact DICERNA PHARMACEUTICALS INC, please visit www.dicerna.com. Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.